研究论文

新型苯丙烯酰氨基酸化合物的设计合成及生物活性

  • 高粟繁 ,
  • 张艳春 ,
  • 李家明 ,
  • 张斌 ,
  • 杨雨 ,
  • 胡孟奇
展开
  • a 安徽中医药大学药学院 合肥 230012;
    b 安徽省中医药科学院药物化学研究所 合肥 230012

收稿日期: 2018-12-19

  修回日期: 2019-02-02

  网络出版日期: 2019-04-08

基金资助

十二五国家科技重大专项(No.2012ZX09401-006)资助项目.

Synthesis and Biological Evaluation of Novel Phenylpropenoyl-amino Acid Derivatives

  • Gao Sufan ,
  • Zhang Yanchun ,
  • Li Jiaming ,
  • Zhang Bin ,
  • Yang Yu ,
  • Hu Mengqi
Expand
  • a College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012;
    b Deparment of Medicinal Chemistry, Anhui Academy of Chinese Medicine, Hefei 230012

Received date: 2018-12-19

  Revised date: 2019-02-02

  Online published: 2019-04-08

Supported by

Project supported by the National Science and Technology Major Project in 12th Five-Year (No. 2012ZX09401-006).

摘要

依据药效团的拼合策略,以上市药瑞巴派特为先导化合物,设计并合成了一系列具有苯丙烯酰氨基酸结构化合物,其结构均经1H NMR、13C NMR和MS确证.用Elisa法测定目标化合物对LPS诱导的RAW264.7细胞释放IL-6和TNF-α的抑制活性.结果显示所设计化合物显示出良好的抑制活性,其中有4个化合物的活性明显优于瑞巴派特.

本文引用格式

高粟繁 , 张艳春 , 李家明 , 张斌 , 杨雨 , 胡孟奇 . 新型苯丙烯酰氨基酸化合物的设计合成及生物活性[J]. 有机化学, 2019 , 39(7) : 1953 -1961 . DOI: 10.6023/cjoc201812037

Abstract

Based on the listed drug rebamipide, a series of novel compounds of phenylpropenoyl-amino acid structures were designed and synthesized according to the pharmacophore-combination strategy. The structures of the target compounds were confirmed by NMR and MS. The inhibitory activities against IL-6 and TNF-α had been investigated. The results demonstrated that all compounds exhibited moderate IL-6 and TNF-α inhibitory activities. In particular, the activities of four compounds were significantly improved than that of rebamipide.

参考文献

[1] Balkwill F. Nat. Rev. Cancer. 1992, 4(2), 121.
[2] Hotamisligil, G. S.; Arner, P.; Caro, J. F. J. Clin. Invest. 1995, 95(5), 2409.
[3] Rus H. G.; Niculescu, F.; Vlaicu, R. Atherosclerosis 1991, 89(2~3), 247.
[4] Guirado, A.; López Sánchez, J. I.; Ruiz-Alcaraz, A. J. Eur. J. Med. Chem. 2012, 54(50), 87.
[5] Hauwermeiren, F. V.; Vandenbroucke, R. E.; Libert, C. Cytokine Growth Factor. Rev. 2011, 22(5), 311.
[6] Gómez-Reino, J. J.; Carmona, L.; Valverde, V. R. Arthritis Rheum-US 2003, 48(8), 2122.
[7] Wei, T.; Lu, Y.; Zhang, Y. Science 2011, 332(6028), 478.
[8] Koike, T.; Harigai, M.; Inokuma, S. Ann. Rheum. Dis. 2011, 70(12), 2148.
[9] Desai, S. B.; Furst, D. E. Best Pract. Res., Clin. Rheumatol. 2006, 20(4), 757.
[10] Bandgarab, B. P.; Korbad, B. L.; Nile, S. H. Eur. J. Med. Chem. 2010, 45(6), 2629.
[11] La, M. I.; Jun, K. I.; Jhun KR 20140016848, 2014.
[12] Li, W. W.; Zhao, Y. P.; Xu, X. L. FEBS J. 2015, 282(12), 2317.
[13] Moon, S. J.; Park, J. S.; Woo, Y. J. Arthritis Rheumatol. 2014, 66(4), 874.
[14] Cho, E. H.; Choi, S. J.; Lee, S. W. EP2987491, 2016.
[15] Li, X. M.; Zhao, M.; Tang, Y. R. Eur. J. Med. Chem. 2008, 43(1), 8.
[16] Leite, A. C. L.; Barbosa, F. F.; Moreira, D. R. M. Med. Chem. Res. 2013, 23(4), 1701.
[17] Papadakis, K. A.; Targan, S. R. Annu. Rev. Med. 2000, 51(1), 289.
[18] Uchida, M.; Tabusa, F.; Komatsu, M.; Morita, S.; Kanbe, T.; Nakagawa, K. Chem. Pharm. Bull. 1986, 34, 4821.
[19] Bashiardes, G.; Safir, I.; Barbot, F. Synlett 2007, 1707.

文章导航

/